Vaccines and disease-modifying treatments
Publication date: Available online 24 October 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Emmanuelle Waubant, Gavin Giovannoni, Chris Hawkes, Michael Levy (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - November 16, 2018 Category: Neurology Source Type: research

Animal exposure over the life-course and risk of multiple sclerosis: a case-control study within two cohorts of US women
ConclusionAnimal exposure, and specifically dog exposure, in early adolescence was associated with an increased risk of MS. Further work is needed to confirm this finding. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - November 16, 2018 Category: Neurology Source Type: research

Autoimmune diseases associated with Neuromyelitis Optica spectrum disorders: A literature review
ConclusionsNMOSD may be associated with a variety of different types of autoimmune diseases. Therefore, systemic or laboratory signs which are not typical for NMOSD should be properly investigated to exclude other associated comorbidities. These comorbidities may affect the treatment strategy and may improve the patients' care and management. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - November 16, 2018 Category: Neurology Source Type: research

Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis
Publication date: Available online 12 November 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): F. Crescenzo, D. Marastoni, C. Zuco, M. Pitteri, R. Magliozzi, S. Monaco, M. CalabreseABSTRACTIntroductionIn this two year longitudinal study we compare the progression of grey matter (GM) damage in MS patients treated with glatiramer acetate (GA) for relapsing-remitting multiple sclerosis (RRMS) respect to untreated patients.MethodsWe studied thirty-five treated with GA and thirty-five untreated RRMS subjects matched for age, gender, disease duration and EDSS. Each patient underwent neurological examination every ...
Source: Multiple Sclerosis and Related Disorders - November 14, 2018 Category: Neurology Source Type: research

Tocilizumab in MOG-antibody spectrum disorder: a case report
ConclusionOur observations suggest that TCZ could induce clinico-radiologic improvements, which make it as an option for the treatment of MOG-SD. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - November 14, 2018 Category: Neurology Source Type: research

Impact of pre-cooling therapy on the physical performance and functional capacity of multiple sclerosis patients: A systematic review
Publication date: Available online 13 November 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Antonia Kaltsatou, Andreas D. FlourisAbstractPatients with multiple sclerosis experience many complications that gradually lead them to comorbidity and disability. Exercise could prevent and ameliorate the symptoms that comorbidity or inactivity generate. However, until recently it was suggested that multiple sclerosis patients should not participate in exercise training programs because multiple sclerosis patients are characterized by thermoregulatory failure and the heat stress due to physical work could exacerba...
Source: Multiple Sclerosis and Related Disorders - November 14, 2018 Category: Neurology Source Type: research

Sequential phases of RGC axonal and somatic injury in EAE mice examined using DTI and OCT
ConclusionsDTI and OCT measures are tightly correlated during the chronic phase of axonal degeneration (4-8 weeks) in EAE mice. After 8 weeks of EAE, both OCT and DTI measures are strong predictors of axon loss in the Optic Nerve. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - November 14, 2018 Category: Neurology Source Type: research

Hiv infection associated neuromyelitis optica spectrum disorder: clinical features, imaging findings, management and outcomes
ConclusionHIV associated NMOSD is a recently recognized entity. A high index of suspicion is needed to diagnose these patients. In all patients with HIV infection presenting with optic neuritis or/and myelitis, anti aquaporin 4 antibody status should be checked and in all patients of NMOSD, HIV infection should be ruled out. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - November 14, 2018 Category: Neurology Source Type: research

Peak width of skeletonized mean diffusivity (PSMD) as marker of widespread white matter tissue damage in multiple sclerosis.
Publication date: Available online 13 November 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): C. Vinciguerra, A. Giorgio, J. Zhang, I. Di Donato, M.L. Stromillo, R. Tappa Brocci, A. Federico, M.T. Dotti, N. De StefanoAbstractBackgroundPeak width of skeletonized mean diffusivity (PSMD) is a novel and fully automated, MRI biomarker, which has shown clinical relevance in cerebral small vessel diseases (SVD). We aimed here to assess PSMD levels across the brain of patients with multiple sclerosis (MS), in comparison to normal controls (NC) and patients with CADASIL, a genetically defined form of severe SVD.Meth...
Source: Multiple Sclerosis and Related Disorders - November 14, 2018 Category: Neurology Source Type: research

Lower self-report fatigue in multiple sclerosis is associated with localized white matter tract disruption between amygdala, temporal pole, insula, and other connected structures.
Publication date: Available online 9 November 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Tom A. Fuchs, Caila B. Vaughn, Ralph H.B. Benedict, Bianca Weinstock-Guttman, Sanjeevani Choudhery, Keith Carolus, Patrick Rooney, Kira Ashton, Deepa Ramasamy, Dejan Jakimovski, Robert Zivadinov, Michael G. DwyerAbstractBackgroundFatigue, a frequent and disabling symptom for people with multiple sclerosis (PwMS), inconsistently correlates with white matter (WM) pathology. Network-based analysis, accounting for the manner in which lesions disrupt networks of structurally connected gray matter (GM) regions, may provid...
Source: Multiple Sclerosis and Related Disorders - November 11, 2018 Category: Neurology Source Type: research

Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: a population-based study
Conclusion: Approximately 1 in 10 individuals discontinued their first oral DMT within 6 months, and 1 in 5 did so within one year. However, among those who did continue drug, a high proportion (>80%) exhibited optimal adherence. Predictors of persistence or adherence with immediate practical application were lacking; this highlights the challenges in optimizing drug therapy. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - November 11, 2018 Category: Neurology Source Type: research

Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?
Publication date: Available online 10 November 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Duygu Kocyigit, Muhammed U Yalcin, Kadri M Gurses, Lale Tokgozoglu, Rana KarabudakAbstractBACKGROUNDFingolimod, a sphingosine-1-phosphate (S1P) receptor agonist, is used for treatment of relapsing-remitting multiple sclerosis (RRMS). S1P receptors that fingolimod acts upon have also been shown to be expressed on atrial myocytes. This expression pattern has been linked with the drug's cardiovascular effects, such as bradycardia. We aimed to evaluate the clinical and electrocardiographic predictors of heart rate (HR)...
Source: Multiple Sclerosis and Related Disorders - November 11, 2018 Category: Neurology Source Type: research

Acute epileptic seizures in myelin oligodendrocyte glycoprotein encephalomyelitis and neuromyelitis optica spectrum disorder: A comparative cohort study
In this study, we compared the incidence and characteristics of acute epileptic seizures in MOG-EM and NMOSD patients.MethodsMOG-EM (n=61) and NMOSD (n=565) cases obtained from the MSNMOBase (2011–2018) were retrospectively reviewed.ResultsAcute epileptic seizures were observed in 13 (21.3%) patients with MOG-EM and two (0.4%) patients with NMOSD (P
Source: Multiple Sclerosis and Related Disorders - November 11, 2018 Category: Neurology Source Type: research

Impact of early diagnosis on clinical characteristics of an Italian sample of people with Multiple Sclerosis recruited online
Conclusionwe showed, verifying a large sample of patients in a reallife setting, that the improvement of the diagnostic process allowed the anticipation of MS diagnosis over years and had a huge impact in terms of treatment approach. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - November 6, 2018 Category: Neurology Source Type: research

Peripapillary Retinal Nerve Fiber Layer Thickness Measured by Optical Coherence Tomography in Different Clinical Subtypes of Multiple Sclerosis
ConclusionsA significant correlation was established between RNFL thickness and progression of neurodegeneration in MS patients with no regard to history of ON. RNFL thickness may be considered a MS biomarker and potential diagnostic tool for assessment of disease progression. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - November 6, 2018 Category: Neurology Source Type: research

The role of phospholipase A2 in multiple Sclerosis: A systematic review and meta-analysis
The objective of this systematic review is to determine the association between PLA2 activity and multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE). We performed a systematic review of six studies that assessed PLA2 activity in MS patients compared to controls and nine studies that assessed PLA2 activity in EAE. sPLA2 nor Lp-PLA2 activity were not increased in MS compared to controls in five of those six studies. A difference in sPLA2 activity was only found in a study that measured the enzyme activity in urine. However, inhibiting cPLA2 or sPLA2 led to lower clinical severity or...
Source: Multiple Sclerosis and Related Disorders - November 6, 2018 Category: Neurology Source Type: research

Paraneoplastic Neuromyelitis Optica Associated with Fever of Unknown Origin as an Early Manifestation: A Case Report
Publication date: Available online 2 November 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Masoud etemadifar, Yalda nikanpour, Amir neshatfar, Fatemeh sabetiAbstractTumors have been frequently reported to be associated with neuromyelitis optica (NMO). Here we review a case of a 34-year-old woman who presented with complaint of one-sided visual loss. All Lab tests exhibited negative results which decreased the possibility of Auto-immune or neuro-inflammatory disorders. Magnetic resonance imaging (MRI) of the brain and spinal cord was done as a part of work up, which showed Meningioma in anterior fossa with...
Source: Multiple Sclerosis and Related Disorders - November 3, 2018 Category: Neurology Source Type: research

Treating the ineligible: disease modification in people with multiple sclerosis beyond NHS England commissioning policies
ConclusionPersonalised dosing of cladribine avoided severe lymphopenia in all but one patients and was very well tolerated across a large spectrum of disease severity. Our data suggests cladribine may offer benefit people with relapsing and progressive MS alike. The personalised protocol used appears safe, however warrants controlled studies to more definitively assess efficacy and safety, particularly in groups of pwMS who are not eligible for licensed DMT including oral cladribine (Mavenclad®). (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - November 3, 2018 Category: Neurology Source Type: research

The coexistence of recurrent cerebral tumefactive demyelinating lesions with longitudinally extensive transverse myelitis and demyelinating neuropathy
Publication date: Available online 3 November 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Jonathan Ciron, Clarisse Carra-Dallière, Xavier Ayrignac, Jean-Philippe Neau, Nicolas Maubeuge, Pierre LabaugeAbstractCombined central and peripheral demyelination (CCPD) is a rare chronic inflammatory disorder of the nervous system. In this article, we report on a CCPD patient with a very unusual pattern of central demyelination, comprising recurrent cerebral tumefactive demyelinating lesions (three times, each one in a new area of the brain) and one episode of longitudinally extensive transverse myelitis. T...
Source: Multiple Sclerosis and Related Disorders - November 3, 2018 Category: Neurology Source Type: research

Which treatment strategies for polyrefractory Neuro-Behçet disease?
Publication date: Available online 1 November 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Frédéric London, Katharina Hohenbichler, Thierry Duprez, Christian Sindic, Vincent van Pesch (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - November 3, 2018 Category: Neurology Source Type: research

The Role of Phospholipase A2 in Multiple Sclerosis. A Systematic Review and Meta-analysis.
The objective of this systematic review is to determine the association between PLA2 activity and multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE). We performed a systematic review of six studies that assessed PLA2 activity in MS patients compared to controls and nine studies that assessed PLA2 activity in EAE. sPLA2 nor Lp-PLA2 activity were not increased in MS compared to controls in five of those six studies. A difference in sPLA2 activity was only found in a study that measured the enzyme activity in urine. However, inhibiting cPLA2 or sPLA2 led to lower clinical severity or...
Source: Multiple Sclerosis and Related Disorders - October 31, 2018 Category: Neurology Source Type: research

A First Investigation of Tongue, Lip, and Jaw Movements in Persons with Dysarthria due to Multiple Sclerosis
ConclusionFindings suggest that speech movements of the tongue are differentially more impaired than those of the lower lip in PwDMS. Particularly the ability to move the tongue with adequate speed during speech was significantly impaired in PwDMS, which may explain, in part, their slowed speech rate. Aberrant jaw kinematics during /ai/ may be a compensatory strategy to maximize speech clarity in the presence of the impaired tongue motor performance. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 30, 2018 Category: Neurology Source Type: research

Disruption of blood-brain barrier integrity associated with brain lesions in Chinese neuromyelitis optica spectrum disorder patients
Publication date: Available online 30 October 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Xiaofan You, Lirong Yan, Xin Li, Ying Pang, Xiaolei Guo, Jing Ye, Hongtao HuAbstractObjectiveThe aims of this study were to report brain characteristic abnormalities and to evaluate the relationship of blood-brain barrier (BBB) disruption and brain lesions in Chinese patients with NMOSD.MethodsBrain magnetic resonance imaging characteristics and cerebrospinal fluid (CSF) laboratory tests of 121 patients with NMOSD at acute attack were reviewed retrospectively. Qalb (CSF albumin/serum albumin) was used for assessment...
Source: Multiple Sclerosis and Related Disorders - October 30, 2018 Category: Neurology Source Type: research

A rare P2RX7 variant in a Hungarian family with Multiple Sclerosis
Publication date: Available online 27 October 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Tobias Zrzavy, Reka Kovacs-Nagy, Eva Reinthaler, Angela Deutschländer, Christiane Schmied, Barbara Kornek, Fritz Leutmezer, Alexander Zimprich (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 27, 2018 Category: Neurology Source Type: research

The contribution of the instrumented Timed-Up-and-Go test to detect falls and fear of falling in people with multiple sclerosis
The objective of our study was to examine the Instrumented Timed-Up-and-Go test (ITUG) in relation to falls and FoF in PwMS. This case-control study comprised 75 participants; 50 PwMS (33 women), aged 44.2 (S.D=7.2) and 25 healthy subjects (18 women) aged 44.4 (S.D=8.6). The ITUG test was evaluated by the APDM Mobility lab (Portland, OR, USA) and was completed under two task conditions, normal and while performing a cognitive test (ITUG-cog). FoF was evaluated by the FES-I questionnaire. PwMS were divided into subgroups of fallers and non-fallers based on their fall history. Total duration to complete the ITUG and ITUG-cog...
Source: Multiple Sclerosis and Related Disorders - October 27, 2018 Category: Neurology Source Type: research

Uncovering the Association Between Fatigue and Fatigability in Multiple Sclerosis Using Cognitive Control
Publication date: Available online 27 October 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Eli K. Cehelyk, Denise Y. Harvey, Meghan L. Grubb, Rasha Jalel, Mohammad S. El-Sibai, Clyde E. Markowitz, Joseph R. Berger, Roy H. Hamilton, Salim ChahinAbstractBackgroundFatigue and cognitive dysfunction are two common symptoms experienced by patients with multiple sclerosis (MS). The relationship between subjective and objective fatigue (fatigability) in MS is poorly understood. Cognitive control tasks might be more conducive to fatigability and more likely to show associations between subjective and objective cog...
Source: Multiple Sclerosis and Related Disorders - October 27, 2018 Category: Neurology Source Type: research

Coexistence of multiple sclerosis and alzheimer's disease: a review
ConclusionIn summary, we highlight a major knowledge gap in our understanding of two potentially common neurological conditions. With the ageing population, and an estimated 2.3 million people living with MS and 46 million with AD or other dementias worldwide, it will become increasingly important to recognize and understand how to manage individuals with these complex comorbid conditions. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 27, 2018 Category: Neurology Source Type: research

Neuromyelitis optica spectrum disorders (NMO-SD) in a Sub-Saharan Africa country: A preliminary study of sixteen senegalese cases
ConclusionThis cohort is the first one compiled in Dakar. African multicentric epidemiological studies are needed. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 26, 2018 Category: Neurology Source Type: research

Lambert–Eaton myasthenic syndrome associated with alemtuzumab administration
ConclusionAlemtuzumab treatment can result in the development of neurologic autoimmune conditions that could mimic MS progression. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 26, 2018 Category: Neurology Source Type: research

Diagnosing and caring for MS in Haiti
Publication date: Available online 24 October 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Emmanuelle Waubant, Aaron Berkowitz, Gavin Giovannoni, Christopher Hawkes, Michael Levy (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 25, 2018 Category: Neurology Source Type: research

Puberty Onset and Pediatric Multiple Sclerosis Activity in Boys
ConclusionsPubertal onset of MS may be associated with increased relapses in boys. Further investigation is indicated to understand the intersection of pubertal effects and MS pathophysiology. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 24, 2018 Category: Neurology Source Type: research

Lambert Eaton Myasthenic Syndrome Associated with Alemtuzumab Administration
Conclusion: Alemtuzumab treatment can result in the development of neurologic autoimmune conditions that could mimic MS progression. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 24, 2018 Category: Neurology Source Type: research

Use of coping strategies in multiple sclerosis: association with demographic and disease-related characteristics
ConclusionClinicians should be aware of several disease and demographic characteristics that are associated with use of potentially maladaptive coping strategies. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 24, 2018 Category: Neurology Source Type: research

Diabetes and anxiety adversely affect cognition in multiple sclerosis
ConclusionComorbidities, including diabetes and anxiety, are associated with cognitive dysfunction in MS. Their presence may contribute to the heterogeneous pattern of impairments seen across individuals and they may represent targets for improved management of cognitive symptoms. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 24, 2018 Category: Neurology Source Type: research

The role of gluten in multiple sclerosis: a systematic review
ConclusionsThere is still not sufficient evidence to state whether gluten plays a role in MS, but limitations of current evidence have been identified and directions of future research have been suggested. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 24, 2018 Category: Neurology Source Type: research

No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany
DiscussionIn our real-world analysis, we confirm the potential of NEDA for the evaluation and surveillance of MS disease activity, progression and therapy efficacy. Despite highly efficient immunomodulatory treatment, NEDA-3 was only preserved in a minority of patients. Monoclonal antibodies may yield best NEDA rates. Further studies are warranted to evaluate the value of the NEDA concept in real-world settings beyond standardized clinical studies. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 24, 2018 Category: Neurology Source Type: research

Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: clinical course and treatment outcome
ConclusionWe showed that patients’ response to the steroid treatment is different between the MOG group and non-MOG group. The results suggest that presence of MOG-Ab influences the treatment outcome and its length. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 21, 2018 Category: Neurology Source Type: research

Multiple sclerosis and the risk of systemic venous thrombosis: a systematic review
Publication date: Available online 17 October 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Omnya Ahmed, Ruth Geraldes, Gabriele DeLuca, Jacqueline Palace (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 18, 2018 Category: Neurology Source Type: research

Aphasic status epilepticus preceding tumefactive left hemisphere lesion in anti-MOG antibody associated disease
ConclusionAutoimmune epilepsy without obvious causative lesion on MRI can be seen in the course of anti-MOG antibody associated demyelinating disease. The subsequent emergence of tumefactive lesion closely located to the epileptic foci may suggest some association between autoimmune epilepsy and demyelinating lesions. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 16, 2018 Category: Neurology Source Type: research

Assessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: A case- control MRI study.
This study aimed to evaluate the possible influence of the most frequent vascular risk factors on brain volume in MS, also exploring the burden of their combined effects.MethodsMS patients with at least one vascular risk factor and a control group of MS patients were enrolled. Patients underwent brain MRI and the volumes of the whole brain (WB), white matter (WM), grey matter (GM), and cortical GM were estimated by SIENAX. Longitudinal atrophy was assessed by SIENA.ResultsThe sample included 326 MS patients, of these 49 (15%) had diabetes mellitus, 44 (13.4%) hypertension and 50 (15.3%) were active smokers. Multiple regres...
Source: Multiple Sclerosis and Related Disorders - October 16, 2018 Category: Neurology Source Type: research

Blood Lead Levels and Multiple Sclerosis: A Case-Control Study
ConclusionIn conclusion, based on our results, BLL was higher in MS patients, compared with healthy individuals. The risk of MS increased 1.17 times per one µg/L increment of blood lead level. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 16, 2018 Category: Neurology Source Type: research

Intrathecal Baclofen for Multiple Sclerosis related spasticity: a twenty year experience
Publication date: Available online 15 October 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Yezen Sammaraiee, Martin Yardley, Liz Keenan, Katrina Buchanan, Val Stevenson, Rachel FarrellAbstractObjectiveEvaluate long-term efficacy and safety of ITB in treating MS-related spasticity over ∼ 20 years of service provision in a single centre.MethodsA single centre prospective observational cohort study was performed. Eligible subjects underwent ITB trial by bolus dose via lumbar puncture and responders proceeded to pump implantation. Demographics, spasticity scores (Ashworth), spasm score (Penn), stiffness, ...
Source: Multiple Sclerosis and Related Disorders - October 16, 2018 Category: Neurology Source Type: research

Response to the Commentary “The effect of C9orf72 intermediate repeat expansions in neurodegenerative and autoimmune diseases” by Biasiotto G and Zanella I.
Publication date: Available online 14 October 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Cinzia Tiloca, Melissa Sorosina, Federica Esposito, Silvia Peroni, Claudia Colombrita, Nicola Ticozzi, Antonia Ratti, Filippo Martinelli Boneschi, Vincenzo Silani (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 14, 2018 Category: Neurology Source Type: research

Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study
ConclusionCladribine-induced immune reconstitution leads to long lasting suppression of intrathecal humoral response, which might be an additional mechanism that enhances the therapeutic effect on disease progression in RRMS patients. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 10, 2018 Category: Neurology Source Type: research

Comparative Effectiveness of Dimethyl Fumarate versus Fingolimod and Teriflunomide among MS Patients Switching from First-Generation Platform Therapies in the US
ConclusionIn this analysis, the effectiveness profiles for those oral DMT users specifically switching from platform therapies are consistent with findings from previous research conducted among all oral DMT users, regardless of prior therapy. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 10, 2018 Category: Neurology Source Type: research

The effect of C9orf72 intermediate repeat expansions in neurodegenerative and autoimmune diseases
Publication date: January 2019Source: Multiple Sclerosis and Related Disorders, Volume 27Author(s): Giorgio Biasiotto, Isabella Zanella (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 10, 2018 Category: Neurology Source Type: research

Relative importance of physical and psychological factors to slowness in people with mild to moderate multiple sclerosis
Conclusion: Muscle strength, particularly the knee joint strength capacity, could be a principal factor determining gait speed in people with mild to moderate MS. Other factors also significantly affect gait speed in this population. The findings from this study could provide guidance in terms of prioritizing actions to improve gait speed in people with MS. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 9, 2018 Category: Neurology Source Type: research

The effect of C9orf72 intermediate repeat expansions in neurodegenerative and autoimmune diseases.
Publication date: Available online 4 October 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Giorgio Biasiotto, Isabella Zanella (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 6, 2018 Category: Neurology Source Type: research

Headache Characteristics in Multiple Sclerosis
ConclusionIn our study, the prevalence of headache among all multiple sclerosis patients was 68%. The results of this study indicate a possible relationship may exist between headache and multiple sclerosis therapies since 80% of patients described headaches after the onset of treatments. The younger start and the shorter duration of interferon beta use caused the higher incidence of headache, but this correlation was not observed in other drugs. Interestingly, medication overuse headache was far more prevalent in multiple sclerosis patients than in previously reported community populations. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - October 5, 2018 Category: Neurology Source Type: research

Leptomeningeal inflammation in multiple sclerosis: insights from animal and human studies
Publication date: Available online 22 September 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Cassie Wicken, James Nguyen, Rahul Karna, Pavan BhargavaAbstractThe presence of leptomeningeal inflammation (LMI) in MS was first identified in 2004 and multiple subsequent studies have confirmed the presence of immune cell collections in the meninges of a subset of MS patients. Pathologically, LMI can range from disorganized immune cell collections in the meninges of patients with relapsing remitting (RRMS) or primary progressive MS (PPMS) to well-organized ectopic lymphoid follicles in secondary progressive MS (...
Source: Multiple Sclerosis and Related Disorders - October 5, 2018 Category: Neurology Source Type: research